Early data from the CRESTONE trial reported an ORR of 36% with seribantumab in patients with NRG1 fusion-positive solid tumors.5 Nonetheless, the compelling efficacy and safety profile of zenocutuzumab supported its accelerated FDA approval, making it the first approved targeted therapy for NRG1-positive NSCLC and pancreatic adenocarcinoma. This evidence concerns the gene NRG1 and pancreatic adenocarcinoma.